Rockefeller Capital Management
AKRO

Rockefeller Capital Management’s Akero Therapeutics AKRO Stock Holding History

Rockefeller Capital Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-313
Closed -$14.9K – 4674
2025
Q3 		$14.9K Buy
+313
New +$15.2K ﹤0.01% 3489
2023
Q1 		– Sell
-100
Closed -$5K – 2023
2022
Q4 		$5K Hold
100
– – ﹤0.01% 3305
2022
Q3 		$3K Buy
+100
New +$1.53K ﹤0.01% 3455

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Rockefeller Capital Management's AKRO Position: Q4 2025 in Review

Rockefeller Capital Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 313 shares — an estimated $14.9K sold.

Rockefeller Capital Management first reported a position in AKRO in Q3 2022 and held it in 3 quarters. The position peaked at $14.9K in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Rockefeller Capital Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Rockefeller Capital Management sold 313 Akero Therapeutics shares in Q4 2025, an estimated $14.9K.
  • Rockefeller Capital Management first reported a position in Akero Therapeutics in Q3 2022 and held it in 3 quarters.
  • Rockefeller Capital Management's Akero Therapeutics position peaked at $14.9K in Q3 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Rockefeller Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.